LAUSR

HighlightsSerum sCD163 levels correlated positively with the disease activity of s‐JIA, even in patients receiving tocilizumab.Serum sCD163 level is a potential diagnostic laboratory criterion for clinical remission in patients with s‐JIA.Serum sCD163 levels profoundly increased with the progress of MAS in s‐JIA.Soluble CD163 is a unique biomarker to evaluate the disease activity, exhibits macrophage activation in s‐JIA. &NA; This study aims to investigate the clinical significance of serum soluble CD163 (sCD163) levels as a predictor of the disease activity of systemic juvenile idiopathic arthritis (s‐JIA). In this study, we examined 63 patients with s‐JIA, four with Epstein‐Barr virus‐induced hemophagocytic lymphohistiocytosis (EBV‐HLH), and seven with Kawasaki disease (KD), along with 14 healthy controls. We quantified serum cytokine levels (sCD163, neopterin, IL‐18, IL‐6) by enzyme‐linked immunosorbent assay and compared the results with the clinical features of s‐JIA. Serum sCD163 levels were significantly elevated in patients with s‐JIA associated macrophage activation syndrome (MAS) and EBV‐HLH compared to those in patients with acute‐phase s‐JIA and KD. In addition, serum sCD163 levels profoundly increased with the progress of MAS and correlated positively with the disease activity of s‐JIA, even in patients receiving tocilizumab. Furthermore, serum sCD163 levels significantly decreased in the inactive phase compared to those in the active phase and normalized in remission. The correlation between macrophage activation and serum sCD163 levels might be a unique indicator of the disease activity and a potential diagnostic laboratory criterion for clinical remission in patients with s‐JIA, including those receiving tocilizumab.